The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.

On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.

Gelonghui FinanceDec 24 14:58

Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction

Analyst UpgradesDec 24 02:20

GSK COVID Antiviral Authorization for Sotrovimab Revoked by FDA

Seeking AlphaDec 24 01:55

GlaxoSmithKline (GSK) Gets a Hold From Barclays

TipRanksDec 21 02:15 · Ratings

GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of...

BenzingaDec 20 17:01

GSK's Combination of Cancer Drugs Shows Positive Results in Late-Stage Trial

WSJDec 20 15:44